Methanobrevibacter smithii: what stool and breath tests tell you

Measuring a major methane producer in the gut

Methanobrevibacter smithii belongs to the archaea, a distinct group of microorganisms. It is not a bacterium. In the human gut, it uses substances including hydrogen and carbon dioxide released by bacterial fermentation to produce methane.

A stool test can look for its DNA and report a relative abundance or a number of gene copies. Depending on the test, targeted quantitative PCR or metagenomic sequencing may be used. Some analyses look for genes associated with methane production, such as mcrA. Tests designed around bacterial 16S sequences can underrepresent archaea.

A DNA result identifies genetic material in the sample. A breath test measures exhaled methane, so it answers a different question. The two may provide complementary information, but a stool result cannot replace a standardized assessment of gas production.

How methane relates to digestive symptoms

Methane production has been linked with slower intestinal transit. A study of 47 people with irritable bowel syndrome and 30 healthy controls found higher amounts of M. smithii DNA, particularly in constipation-predominant IBS; 25 participants with IBS underwent breath testing. DNA abundance was associated with stool frequency and breath methane. This is a meaningful clinical association, but it does not establish that a DNA result alone explains someone’s symptoms.

Constipation and persistent bloating fit this pattern for some people. The connection makes M. smithii worth studying, without making it the explanation for every case of constipation. Medicines, thyroid function, pelvic floor problems, fluid intake and other factors can also matter.

M. smithii depends on products made by other microbes. Its effects therefore depend on the wider fermentation network. A high proportion of its DNA does not translate automatically into a particular amount of methane. Conversely, a relevant breath methane result can occur alongside an unremarkable stool profile.

In practice, the useful details are bowel movement frequency, stool consistency, straining, symptoms and how they have changed over time. Everyone’s intestinal transit need not follow the same timetable. The aim is to recognize troublesome symptoms and treatable causes, not to eliminate all methane production.

When methane may be worth investigating

Constipation that persists despite reasonable first steps can be a reason to discuss further assessment. Antibiotics, bowel preparation and major dietary changes can also alter archaea and bacteria. These events belong in the history used to interpret a result.

When small intestinal bacterial overgrowth is being considered, excessive methanogen activity is a related but separate question. The term is intestinal methanogen overgrowth, or IMO. Archaea can live in both the small and large intestine; a stool test cannot reliably show where they are located.

A before-and-after comparison is useful only when the testing method, clinical goal and consequences of the result are clear. A falling DNA value without any improvement in symptoms is not automatically a successful treatment outcome.

Reading abundance, gene copies and detection results

A report might say “present” or “not detected,” or give a relative abundance or gene copies per gram. Relative and absolute measurements describe different things. Some people have low or undetectable signals; others have more methanogens. This does not establish a universal ideal value.

The North American breath testing consensus suggests a methane concentration of at least 10 parts per million, or ppm, as a positive result. This means a concentration, not a rise of 10 ppm. It is a breath gas threshold, not a cutoff for a stool DNA percentage, and it needs to be read alongside the testing protocol. A laboratory’s DNA comparison range serves a different purpose.

A prominent M. smithii finding together with a compatible breath test and constipation can make methane a more relevant question. On its own, the stool finding establishes neither IMO nor another disease. A low value does not certify an intact intestinal barrier or optimal fermentation either.

Other investigations depend on the symptoms: thyroid tests or assessment of other causes may be appropriate. Fecal calprotectin addresses intestinal inflammation; it is not a routine companion test for every methane finding.

What an M. smithii result adds

A stool sample mainly reflects the contents of the colon. How well an analysis detects archaea depends heavily on its method and reference database. Diet, antibiotics and sample handling can influence the result. Age and individual bowel function also help shape the pattern.

Keeping the questions separate makes the findings easier to use. Stool testing describes genetic material in a sample. Breath testing measures a gas under defined conditions. Clinical assessment considers whether, and how, either finding fits the person’s symptoms.

Frequently asked questions

What does a Methanobrevibacter smithii test measure?

A targeted stool test detects DNA from this archaeal species and estimates its quantity or relative abundance. It does not directly measure methane production. A broader microbiome profile may identify other organisms, but its methods need to capture archaea adequately.

How is the sample collected?

For a stool test, you collect a small sample, label it and send it according to the kit instructions. Breath tests have their own preparation and measurement requirements. The right procedure depends on the question being investigated.

What can the result tell me about symptoms?

It can show that an important methane producer is present. That may be biologically relevant in constipation. Whether methane contributes to the symptoms is better assessed by combining functional measurements with a clinical evaluation.

How reliable is the analysis?

Targeted PCR and suitable metagenomic methods can detect archaea. Bacteria-focused methods may underestimate them. Gene copies are not a direct measure of activity, either. Small differences between laboratories should not be treated as certain biological changes.

How often should I be tested?

There is no clear standard for routine annual monitoring. During a specific treatment, the clinical question determines whether another test is useful and which method fits. Symptoms and bowel function remain important measures of progress.

Can methanogen populations change quickly?

Yes. Medicines and diet can shift the signals over a short period. Understanding whether a change lasts often requires longer observation. Avoid last-minute attempts to “optimize” your result before a clinically necessary investigation; follow the preparation instructions instead.

Does a high stool value make a diagnosis?

No. It may support further investigation, but it does not diagnose IMO by itself. A high relative abundance also does not prove that the organisms are colonizing the small intestine.

What might help after an unusual result?

Start by clarifying the cause of the constipation or other symptoms. Fiber intake needs to be adjusted to the individual; a sudden large increase can worsen bloating. A DNA percentage alone does not justify antibiotics or another targeted treatment. Your clinician can help decide whether a standardized breath test, a medication review or another assessment would be useful.

Sources

• Ghoshal U, Shukla R, Srivastava D, Ghoshal UC (2016). Irritable bowel syndrome, particularly the constipation-predominant form, involves an increase in Methanobrevibacter smithii, which is associated with higher methane production. Gut and Liver, 10(6), 932-938. https://doi.org/10.5009/gnl15588 PubMed

• Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, Hassoun A, Pateiro M, Lorenzo JM, Rusu AV, Aadil RM (2022). Human gut microbiota in health and disease: Unveiling the relationship. Frontiers in Microbiology, 13, 999001. https://doi.org/10.3389/fmicb.2022.999001 PubMed

• Jovel J, Patterson J, Wang W, Hotte N, O’Keefe S, Mitchel T, Perry T, Kao D, Mason AL, Madsen KL, Wong, G. K.-S. (2016). Characterization of the gut microbiome using 16S or shotgun metagenomics. Frontiers in Microbiology, 7, 459. https://doi.org/10.3389/fmicb.2016.00459 PubMed

• Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F, Lener E, Mele MC, Gasbarrini A, Collado MC, Cammarota G, Ianiro G (2023). Short-chain fatty-acid-producing bacteria: Key components of the human gut microbiota. Nutrients, 15(9), 2211. https://doi.org/10.3390/nu15092211 PubMed

• Drago L (2025). Navigating microbiome variability: Implications for research, diagnostics, and direct-to-consumer testing. Frontiers in Microbiology, 16, 1580531. https://doi.org/10.3389/fmicb.2025.1580531 PubMed

• Rezaie A et al. (2017). Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. PubMed.